Structural effects of HIV-1 subtype C integrase mutations on the activity of integrase strand transfer inhibitors in South African patients

References

• Abram, M. E., Hluhanich, R. M., Goodman, D. D., Andreatta, K. N., Margot, N. A., Ye, L., Niedziela-Majka, A., Barnes, T. L., Novikov, N., Chen, X., Svarovskaia, E. S., McColl, D. J., White, K. L., & Miller, M. D. (2013). Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrobial Agents and Chemotherapy, 57(6), 2654–2663. https://doi.org/10.1128/AAC.02568-12
   PubMed Web of Science ®Google Scholar
• Ahmed, N., Flavell, S., Ferns, B., Frampton, D., Edwards, S. G., Miller, R. F., Grant, P., Nastouli, E., & Gupta, R. K. (2019). Development of the R263K mutation to dolutegravir in an HIV-1 subtype D virus harboring 3 class-drug resistance. Open Forum Infectious Diseases, 6(1), ofy329. https://doi.org/10.1093/ofid/ofy329
   PubMed Web of Science ®Google Scholar
• Ali, S. A., Hassan, M. I., Islam, A., & Ahmad, F. (2014). A review of methods available to estimate solvent-accessible surface areas of soluble proteins in the folded and unfolded states. Current Protein & Peptide Science, 15(5), 456–476. https://doi.org/10.2174/1389203715666140327114232
   PubMed Web of Science ®Google Scholar
• Allen, B., Nisthal, A., & Mayo, S. L. (2010). Experimental library screening demonstrates the successful application of computational protein design to large structural ensembles. Proceedings of the National Academy of Sciences of the United States of America, 107(46), 19838–19843. https://doi.org/10.1073/pnas.1012985107
   PubMed Web of Science ®Google Scholar
• Anstett, K., Cutillas, V., Fusco, R., Mesplède, T., & Wainberg, M. A. (2016). Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity. The Journal of Antimicrobial Chemotherapy, 71(8), 2083–2088. https://doi.org/10.1093/jac/dkw109
   PubMed Web of Science ®Google Scholar
• Benkert, P., Biasini, M., & Schwede, T. (2011). Toward the estimation of the absolute quality of individual protein structure models. Bioinformatics (Oxford, England), 27(3), 343–350. https://doi.org/10.1093/bioinformatics/btq662
   PubMed Web of Science ®Google Scholar
• Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., & Bourne, P. E. (2000). The protein data bank. Nucleic Acids Research, 28(1), 235–242. https://doi.org/10.1093/nar/28.1.235
   PubMed Web of Science ®Google Scholar
• Bessong, P., & Nwobegahay, J. (2013). Genetic analysis of HIV-1 integrase sequences from treatment naive individuals in northeastern South Africa. International Journal of Molecular Sciences, 14(3), 5013–5024. https://doi.org/10.3390/ijms14035013
   PubMed Web of Science ®Google Scholar
• Bienert, S., Waterhouse, A., de Beer, T. A. P., Tauriello, G., Studer, G., Bordoli, L., & Schwede, T. (2017). The SWISS-MODEL repository-new features and functionality. Nucleic Acids Research, 45(D1), D313–D319. https://doi.org/10.1093/nar/gkw1132
   PubMed Web of Science ®Google Scholar
• Blanco, J.-L., Varghese, V., Rhee, S.-Y., Gatell, J. M., & Shafer, R. W. (2011). HIV-1 integrase inhibitor resistance and its clinical implications. The Journal of Infectious Diseases, 203(9), 1204–1214. https://doi.org/10.1093/infdis/jir025
   PubMed Web of Science ®Google Scholar
• Brado, D., Obasa, A. E., Ikomey, G. M., Cloete, R., Singh, K., Engelbrecht, S., Neogi, U., & Jacobs, G. B. (2018). Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and available of integrase inhibitors in Cape Town, South Africa. Scientific Reports, 8(1), 4709–4709. https://doi.org/10.1038/s41598-018-22914-5
   PubMedGoogle Scholar
• Case, D. A. (2018). AMBER 2018 manual.
   Google Scholar
• Ceccherini-Silberstein, F., Van Baelen, K., Armenia, D., Trignetti, M., Rondelez, E., Fabeni, L., Scopelliti, F., Pollicita, M., Van Wesenbeeck, L., Van Eygen, V., Dori, L., Sarmati, L., Aquaro, S., Palamara, G., Andreoni, M., Stuyver, L. J., & Perno, C. F. (2010). Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrobial Agents and Chemotherapy, 54(9), 3938–3948. https://doi.org/10.1128/AAC.01720-09
   PubMed Web of Science ®Google Scholar
• de Carvalho, L. L., Maltarollo, V. G., de Lima, E. F., Weber, K. C., Honorio, K. M., & da Silva, A. B. F. (2014). Molecular features related to HIV integrase inhibition obtained from structure- and ligand-based approaches. PLoS One, 9(1), e81301. https://doi.org/10.1371/journal.pone.0081301
   PubMed Web of Science ®Google Scholar
• Dixit, S. B., Ponomarev, S. Y., & Beveridge, D. L. (2006). Root mean square deviation probability analysis of molecular dynamics trajectories on DNA. Journal of Chemical Information and Modeling, 46(3), 1084–1093. https://doi.org/10.1021/ci0504925
   PubMed Web of Science ®Google Scholar
• Durham, S. H., & Chahine, E. B. (2021). Cabotegravir-rilpivirine: The first complete long-acting injectable regimen for the treatment of HIV-1 infection. Annals of Pharmacotherapy, 1060028021995586.
   Web of Science ®Google Scholar
• Engelman, A. N. (2019). Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition. The Journal of Biological Chemistry, 294(41), 15137–15157. https://doi.org/10.1074/jbc.REV119.006901
   PubMed Web of Science ®Google Scholar
• Eurtivong, C., Choowongkomon, K., Ploypradith, P., & Ruchirawat, S. (2019). Molecular docking study of lamellarin analogues and identification of potential inhibitors of HIV-1 integrase strand transfer complex by virtual screening. Heliyon, 5(11), e02811. https://doi.org/10.1016/j.heliyon.2019.e02811
   PubMed Web of Science ®Google Scholar
• Genheden, S., & Ryde, U. (2015). The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion on Drug Discovery, 10(5), 449–461. https://doi.org/10.1517/17460441.2015.1032936
   PubMed Web of Science ®Google Scholar
• Goethals, O., Clayton, R., Van Ginderen, M., Vereycken, I., Wagemans, E., Geluykens, P., Dockx, K., Strijbos, R., Smits, V., Vos, A., Meersseman, G., Jochmans, D., Vermeire, K., Schols, D., Hallenberger, S., & Hertogs, K. (2008). Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. Journal of Virology, 82(21), 10366–10374. https://doi.org/10.1128/JVI.00470-08
   PubMed Web of Science ®Google Scholar
• Graham, M. J., Drake, A. J., Djorgovski, S. G., Mahabal, A. A., & Donalek, C. (2013). Using conditional entropy to identify periodicity. Monthly Notices of the Royal Astronomical Society, 434(3), 2629–2635. https://doi.org/10.1093/mnras/stt1206
   Web of Science ®Google Scholar
• Greenwald, J., Le, V., Butler, S. L., Bushman, F. D., & Choe, S. (1999). The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity. Biochemistry, 38(28), 8892–8898. https://doi.org/10.1021/bi9907173
   PubMed Web of Science ®Google Scholar
• Hachiya, A., Ode, H., Matsuda, M., Kito, Y., Shigemi, U., Matsuoka, K., Imamura, J., Yokomaku, Y., Iwatani, Y., & Sugiura, W. (2015). Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance. Antiviral Research, 119, 84–88. https://doi.org/10.1016/j.antiviral.2015.04.014
   PubMed Web of Science ®Google Scholar
• Hanwell, M. D., Curtis, D. E., Lonie, D. C., Vandermeersch, T., Zurek, E., & Hutchison, G. R. (2012). Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. Journal of Cheminformatics, 4(1), 17. https://doi.org/10.1186/1758-2946-4-17
   PubMed Web of Science ®Google Scholar
• Harper, A. L., Skinner, L. M., Sudol, M., & Katzman, M. (2001). Use of patient-derived human immunodeficiency virus type 1 integrases to identify a protein residue that affects target site selection. Journal of Virology, 75(16), 7756–7762. https://doi.org/10.1128/JVI.75.16.7756-7762.2001
   PubMed Web of Science ®Google Scholar
• Harper, A. L., Sudol, M., & Katzman, M. (2003). An amino acid in the central catalytic domain of three retroviral integrases that affects target site selection in nonviral DNA. Journal of Virology, 77(6), 3838–3845. https://doi.org/10.1128/jvi.77.6.3838-3845.2003
   PubMed Web of Science ®Google Scholar
• Hayes, J. M., & Archontis, G. (2012). MM-GB (PB) SA calculations of protein-ligand binding free energies. Molecular Dynamics-Studies of Synthetic and Biological Macromolecules, 171–190. ISBN 978-953-51-0444-5.
   Google Scholar
• Hazuda, D. J. (2009). Resistance to inhibitors of human immunodeficiency virus type I integration, in antimicrobial drug resistance (pp. 507–517). Springer.
   Google Scholar
• Hazuda, D., Nguyen, B. M., & Zhao, J., for the P005 Study team. (2007). Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a Phase II study in patients with triple-class resistance HIV-infection. XVI International HIV Drug Resistance Workshop: Basic Principles and Clinical implications.
   Google Scholar
• Hurt, C. B., Sebastian, J., Hicks, C. B., & Eron, J. J. (2014). Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009–2012. Clinical Infectious Diseases, 58(3), 423–431. https://doi.org/10.1093/cid/cit697
   PubMed Web of Science ®Google Scholar
• Isaacs, D. (2020). Structural comparison of diverse HIV-1 subtypes using molecular modelling and docking analyses of Integrase inhibitors. Viruses, 12(9), 936. https://doi.org/10.3390/v12090936
   PubMed Web of Science ®Google Scholar
• Karimipour, A., Amini, A., Nouri, M., D'Orazio, A., Sabetvand, R., Hekmatifar, M., Marjani, A., & Bach, Q.-V. (2021). Molecular dynamics performance for coronavirus simulation by C, N, O, and S atoms implementation dreiding force field: Drug delivery atomic interaction in contact with metallic Fe, Al, and steel. Computational Particle Mechanics, 8, 737-749. https://doi.org/10.1007/s40571-020-00367-w
   Google Scholar
• Malet, I., Delelis, O., Valantin, M.-A., Montes, B., Soulie, C., Wirden, M., Tchertanov, L., Peytavin, G., Reynes, J., Mouscadet, J.-F., Katlama, C., Calvez, V., & Marcelin, A.-G. (2008). Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrobial Agents and Chemotherapy, 52(4), 1351–1358. https://doi.org/10.1128/AAC.01228-07
   PubMed Web of Science ®Google Scholar
• Malet, I., Gimferrer Arriaga, L., Artese, A., Costa, G., Parrotta, L., Alcaro, S., Delelis, O., Tmeizeh, A., Katlama, C., Valantin, M.-A., Ceccherini-Silberstein, F., Calvez, V., & Marcelin, A.-G. (2014). New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. The Journal of Antimicrobial Chemotherapy, 69(8), 2118–2122. https://doi.org/10.1093/jac/dku095
   PubMed Web of Science ®Google Scholar
• Marchand, C., Zhang, X., Pais, G. C. G., Cowansage, K., Neamati, N., Burke, T. R., & Pommier, Y. (2002). Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. The Journal of Biological Chemistry, 277(15), 12596–12603. https://doi.org/10.1074/jbc.M110758200
   PubMed Web of Science ®Google Scholar
• Martin, A. J. M., Vidotto, M., Boscariol, F., Di Domenico, T., Walsh, I., & Tosatto, S. C. E. (2011). RING: Networking interacting residues, evolutionary information and energetics in protein structures. Bioinformatics (Oxford, England), 27(14), 2003–2005. https://doi.org/10.1093/bioinformatics/btr191
   PubMed Web of Science ®Google Scholar
• Mayo, S. L., Olafson, B. D., & Goddard, W. A. (1990). DREIDING: A generic force field for molecular simulations. The Journal of Physical Chemistry, 94(26), 8897–8909. https://doi.org/10.1021/j100389a010
   Web of Science ®Google Scholar
• McColl, D. J., & Chen, X. (2010). Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy. Antiviral Research, 85(1), 101–118. https://doi.org/10.1016/j.antiviral.2009.11.004
   PubMed Web of Science ®Google Scholar
• Métifiot, M., Maddali, K., Naumova, A., Zhang, X., Marchand, C., & Pommier, Y. (2010). Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir. Biochemistry, 49(17), 3715–3722. https://doi.org/10.1021/bi100130f
   PubMed Web of Science ®Google Scholar
• Moorhouse, M. A. (2018). Southern African HIV Clinicians Society guidance on the use of dolutegravir in first-line antiretroviral therapy. Southern African Journal of HIV Medicine,19(1), 1–2.
   Google Scholar
• Oliveira, M., Mesplède, T., Quashie, P. K., Moïsi, D., & Wainberg, M. A. (2014). Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS (London, England), 28(6), 813–819. https://doi.org/10.1097/QAD.0000000000000199
   PubMed Web of Science ®Google Scholar
• Pace, C. N., Fu, H., Lee Fryar, K., Landua, J., Trevino, S. R., Schell, D., Thurlkill, R. L., Imura, S., Scholtz, J. M., Gajiwala, K., Sevcik, J., Urbanikova, L., Myers, J. K., Takano, K., Hebert, E. J., Shirley, B. A., & Grimsley, G. R. (2014). Contribution of hydrogen bonds to protein stability. Protein Science: A Publication of the Protein Society, 23(5), 652–661. https://doi.org/10.1002/pro.2449
   PubMed Web of Science ®Google Scholar
• Passos, D. O., Li, M., Yang, R., Rebensburg, S. V., Ghirlando, R., Jeon, Y., Shkriabai, N., Kvaratskhelia, M., Craigie, R., & Lyumkis, D. (2017). Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome. Science (New York, N.Y.), 355(6320), 89–92. https://doi.org/10.1126/science.aah5163
   PubMed Web of Science ®Google Scholar
• Perryman, A. L., Forli, S., Morris, G. M., Burt, C., Cheng, Y., Palmer, M. J., Whitby, K., McCammon, J. A., Phillips, C., & Olson, A. J. (2010). A dynamic model of HIV integrase inhibition and drug resistance. Journal of Molecular Biology, 397(2), 600–615. https://doi.org/10.1016/j.jmb.2010.01.033
   PubMed Web of Science ®Google Scholar
• Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004). UCSF Chimera-A visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25(13), 1605–1612. https://doi.org/10.1002/jcc.20084
   PubMed Web of Science ®Google Scholar
• Quashie, P. K., Han, Y.-S., Hassounah, S., Mesplède, T., & Wainberg, M. A. (2015). Structural studies of the HIV-1 integrase protein: Compound screening and characterization of a DNA-binding inhibitor. PLoS One, 10(6), e0128310. https://doi.org/10.1371/journal.pone.0128310
   PubMed Web of Science ®Google Scholar
• Quashie, P. K., Mesplède, T., & Wainberg, M. A. (2013). Evolution of HIV integrase resistance mutations. Current Opinion in Infectious Diseases, 26(1), 43–49. https://doi.org/10.1097/QCO.0b013e32835ba81c
   PubMed Web of Science ®Google Scholar
• Rastelli, G., Del Rio, A., Degliesposti, G., & Sgobba, M. (2010). Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA. Journal of Computational Chemistry, 31(4), 797–810. https://doi.org/10.1002/jcc.21372
   PubMed Web of Science ®Google Scholar
• Sachithanandham, J., Konda Reddy, K., Solomon, K., David, S., Kumar Singh, S., Vadhini Ramalingam, V., Alexander Pulimood, S., Cherian Abraham, O., Rupali, P., Sridharan, G., & Kannangai, R. (2016). Effect of HIV-1 Subtype C integrase mutations implied using molecular modeling and docking data. Bioinformation, 12(3), 221–230. https://doi.org/10.6026/97320630012221
   PubMed Web of Science ®Google Scholar
• Serrao, E., Odde, S., Ramkumar, K., & Neamati, N. (2009). Raltegravir, elvitegravir, and metoogravir: The birth of "me-too" HIV-1 integrase inhibitors. Retrovirology, 6(1), 33–14. https://doi.org/10.1186/1742-4690-6-33
   Google Scholar
• Smith, S. J., Zhao, X. Z., Passos, D. O., Pye, V. E., Cherepanov, P., Lyumkis, D., Burke, T. R., & Hughes, S. H. (2021). HIV-1 integrase inhibitors with modifications that affect their potencies against drug resistant integrase mutants. ACS Infectious Diseases, 7(6), 1469–1482. https://doi.org/10.1021/acsinfecdis.0c00819
   PubMed Web of Science ®Google Scholar
• Sotriffer, C. A., Ni, H., & McCammon, J. A. (2000). HIV-1 integrase inhibitor interactions at the active site: Prediction of binding modes unaffected by crystal packing. Journal of the American Chemical Society, 122(25), 6136–6137. https://doi.org/10.1021/ja001152x
   Web of Science ®Google Scholar
• Sun, H., Duan, L., Chen, F., Liu, H., Wang, Z., Pan, P., Zhu, F., Zhang, J. Z. H., & Hou, T. (2018). Assessing the performance of MM/PBSA and MM/GBSA methods. 7. Entropy effects on the performance of end-point binding free energy calculation approaches. Physical Chemistry Chemical Physics: PCCP, 20(21), 14450–14460. https://doi.org/10.1039/c7cp07623a
   PubMed Web of Science ®Google Scholar
• Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461. https://doi.org/10.1002/jcc.21334
   PubMed Web of Science ®Google Scholar
• Van Wesenbeeck, L., Rondelez, E., Feyaerts, M., Verheyen, A., Van der Borght, K., Smits, V., Cleybergh, C., De Wolf, H., Van Baelen, K., & Stuyver, L. J. (2011). Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrobial Agents and Chemotherapy, 55(1), 321–325. https://doi.org/10.1128/AAC.01733-09
   PubMed Web of Science ®Google Scholar
• Vlachakis, D. (2014). Current state-of-the-art molecular dynamics methods and applications. Advances in protein chemistry and structural biology, 94, 269–313.
   Google Scholar
• Voelker, R. (2021). Monthly injection is approved for patients with HIV. JAMA, 325(9), 816–816. https://doi.org/10.1001/jama.2021.1932
   Web of Science ®Google Scholar
• Wainberg, M. A., Mesplede, T., & Quashie, P. K. (2012). The development of novel HIV integrase inhibitors and the problem of drug resistance. Current Opinion in Virology, 2(5), 656–662. https://doi.org/10.1016/j.coviro.2012.08.007
   PubMed Web of Science ®Google Scholar
• Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F. T., de Beer, T. A. P., Rempfer, C., Bordoli, L., Lepore, R., & Schwede, T. (2018). SWISS-MODEL: Homology modelling of protein structures and complexes. Nucleic Acids Research, 46(W1), W296–W303. https://doi.org/10.1093/nar/gky427
   PubMed Web of Science ®Google Scholar
• Yang, Z., Lasker, K., Schneidman-Duhovny, D., Webb, B., Huang, C. C., Pettersen, E. F., Goddard, T. D., Meng, E. C., Sali, A., & Ferrin, T. E. (2012). UCSF Chimera, MODELLER, and IMP: An integrated modeling system. Journal of Structural Biology, 179(3), 269–278. https://doi.org/10.1016/j.jsb.2011.09.006
   PubMed Web of Science ®Google Scholar
• Ylilauri, M., & Pentikäinen, O. T. (2013). MMGBSA as a tool to understand the binding affinities of filamin-peptide interactions. Journal of Chemical Information and Modeling, 53(10), 2626–2633. https://doi.org/10.1021/ci4002475
   PubMed Web of Science ®Google Scholar